Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead
Key result
Antihypertensive agents modulating the renin-angiotensin-aldosterone system can delay microalbuminuria progression and decrease cardiovascular morbidity and mortality in patients with diabetes.
Population
Patients with diabetes and/or hypertension with microalbuminuria
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Confirms RAAS blockade benefits in diabetes; leaves open contribution of anti-inflammatory targeting.
Structured PICO
P
Population
Patients with diabetes and/or hypertension with microalbuminuria
I
Intervention
Antihypertensive agents that modulate the renin-angiotensin-aldosterone system (RAAS)
RAAS-blocking agents can delay microalbuminuria progression and reduce cardiovascular morbidity and mortality in diabetic patients, though the impact of targeting underlying inflammation remains to be determined.
Limitations
- It remains to be determined whether targeting the underlying inflammatory process can retard or prevent microalbuminuria progression or whether treatment can prevent end-stage renal disease or death.
Cite This Study
Kalaitzidis et al. (2009) conducted a review in Microalbuminuria in patients with diabetes. Renin-angiotensin-aldosterone system (RAAS) modulating agents was evaluated. Antihypertensive agents modulating the renin-angiotensin-aldosterone system can delay microalbuminuria progression and decrease cardiovascular morbidity and mortality in patients with diabetes.